RU2004110053A - Производные лактама в качестве антагонистов 11cby рецепторов человека - Google Patents
Производные лактама в качестве антагонистов 11cby рецепторов человека Download PDFInfo
- Publication number
- RU2004110053A RU2004110053A RU2004110053/04A RU2004110053A RU2004110053A RU 2004110053 A RU2004110053 A RU 2004110053A RU 2004110053/04 A RU2004110053/04 A RU 2004110053/04A RU 2004110053 A RU2004110053 A RU 2004110053A RU 2004110053 A RU2004110053 A RU 2004110053A
- Authority
- RU
- Russia
- Prior art keywords
- formula
- group
- compound
- compound according
- compounds
- Prior art date
Links
- 150000003951 lactams Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 48
- 150000003839 salts Chemical class 0.000 claims abstract 7
- 239000012453 solvate Substances 0.000 claims abstract 5
- 238000000034 method Methods 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000002619 bicyclic group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical group OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- 239000002585 base Substances 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- -1 methoxymethoxy Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- QMNWYGTWTXOQTP-UHFFFAOYSA-N 1h-triazin-6-one Chemical compound O=C1C=CN=NN1 QMNWYGTWTXOQTP-UHFFFAOYSA-N 0.000 claims 2
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 claims 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 2
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 239000000010 aprotic solvent Substances 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 229910052763 palladium Inorganic materials 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 claims 1
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical compound C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 claims 1
- PZMKGWRBZNOIPQ-UHFFFAOYSA-N 1h-thieno[3,2-d]pyrimidin-4-one Chemical compound OC1=NC=NC2=C1SC=C2 PZMKGWRBZNOIPQ-UHFFFAOYSA-N 0.000 claims 1
- OSEVYTJMMHAQGG-UHFFFAOYSA-N 2-methylsulfanyl-1h-thieno[3,2-d]pyrimidin-4-one Chemical compound N1C(SC)=NC(=O)C2=C1C=CS2 OSEVYTJMMHAQGG-UHFFFAOYSA-N 0.000 claims 1
- SZDUJHZOLZGLMV-UHFFFAOYSA-N 2-sulfanylidene-1h-thieno[3,2-d]pyrimidin-4-one Chemical compound O=C1NC(=S)NC2=C1SC=C2 SZDUJHZOLZGLMV-UHFFFAOYSA-N 0.000 claims 1
- IVRCHBYBKXRNIC-UHFFFAOYSA-N 3-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]-6-phenylthieno[3,2-d]pyrimidin-4-one Chemical compound COC1=CC(N2C(C=3SC(=CC=3N=C2)C=2C=CC=CC=2)=O)=CC=C1OCCN1CCCC1 IVRCHBYBKXRNIC-UHFFFAOYSA-N 0.000 claims 1
- QJDUIALZROAHNX-UHFFFAOYSA-N 3-[3-methoxy-4-(2-pyrrolidin-1-ylethyl)phenyl]-7-phenyl-1,2,3-benzotriazin-4-one Chemical compound COC1=CC(N2C(C3=CC=C(C=C3N=N2)C=2C=CC=CC=2)=O)=CC=C1CCN1CCCC1 QJDUIALZROAHNX-UHFFFAOYSA-N 0.000 claims 1
- JEDVKUHCDPPWNR-UHFFFAOYSA-N 3h-thieno[2,3-d]pyrimidin-4-one Chemical compound O=C1NC=NC2=C1C=CS2 JEDVKUHCDPPWNR-UHFFFAOYSA-N 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 206010001597 Alcohol interaction Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010051161 Hyperglucagonaemia Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 239000007868 Raney catalyst Substances 0.000 claims 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims 1
- 229910000564 Raney nickel Inorganic materials 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 238000006069 Suzuki reaction reaction Methods 0.000 claims 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 claims 1
- 150000008046 alkali metal hydrides Chemical class 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 150000001350 alkyl halides Chemical class 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 150000001543 aryl boronic acids Chemical class 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000009835 boiling Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 238000006193 diazotization reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000035880 hyperglucagonemia Effects 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 150000003949 imides Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000003586 protic polar solvent Substances 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/10—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D257/12—Six-membered rings having four nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0124627.1 | 2001-10-15 | ||
| GBGB0124627.1A GB0124627D0 (en) | 2001-10-15 | 2001-10-15 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004110053A true RU2004110053A (ru) | 2005-10-20 |
Family
ID=9923785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004110053/04A RU2004110053A (ru) | 2001-10-15 | 2002-10-15 | Производные лактама в качестве антагонистов 11cby рецепторов человека |
Country Status (21)
| Country | Link |
|---|---|
| EP (2) | EP1436267B1 (https=) |
| JP (2) | JP2005508966A (https=) |
| KR (2) | KR20050043724A (https=) |
| CN (2) | CN1596247A (https=) |
| AT (2) | ATE349434T1 (https=) |
| BR (2) | BR0213242A (https=) |
| CA (2) | CA2463509A1 (https=) |
| CO (2) | CO5580779A2 (https=) |
| CZ (2) | CZ2004498A3 (https=) |
| DE (2) | DE60218721T2 (https=) |
| ES (2) | ES2279009T3 (https=) |
| GB (1) | GB0124627D0 (https=) |
| HU (2) | HUP0402346A2 (https=) |
| IL (2) | IL160872A0 (https=) |
| MX (2) | MXPA04003534A (https=) |
| NO (2) | NO20041503L (https=) |
| NZ (1) | NZ531911A (https=) |
| PL (2) | PL370587A1 (https=) |
| RU (1) | RU2004110053A (https=) |
| WO (2) | WO2003033476A1 (https=) |
| ZA (2) | ZA200402672B (https=) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040058307A (ko) | 2001-11-26 | 2004-07-03 | 쉐링 코포레이션 | 비만 및 ｃｎｓ 장애를 치료하기 위한 피페리딘계 ｍｃｈ길항제 |
| AU2002352878B2 (en) | 2001-11-27 | 2007-11-22 | Merck Sharp & Dohme Corp. | 2-Aminoquinoline compounds |
| DE10238865A1 (de) * | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US7351719B2 (en) | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US20060194871A1 (en) * | 2003-04-11 | 2006-08-31 | Barvian Kevin K | Heterocyclic mchr1 antagoists |
| EP1657242A4 (en) * | 2003-08-15 | 2008-10-29 | Banyu Pharma Co Ltd | imidazopyridine |
| KR100747042B1 (ko) * | 2003-08-19 | 2007-08-07 | 솔젠트 (주) | 신물질６-메틸-３-펜에틸-３,４-디히드로-１ｈ-큐나졸린-２-티온,이의 제조방법 및 이를 유효성분으로 포함하는 미백 효능조성물 |
| JP2007509158A (ja) * | 2003-10-23 | 2007-04-12 | グラクソ グループ リミテッド | 肥満、糖尿病、うつ病及び不安を治療するためのｍｃｈｒ１アンタゴニストとしての３−（４−アミノフェニル）チエノピリミド−４−オン誘導体 |
| US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
| RU2358969C2 (ru) * | 2004-02-13 | 2009-06-20 | Баниу Фармасьютикал Ко., Лтд. | Конденсированное 4-оксопиримидиновое производное |
| DE102004010893A1 (de) * | 2004-03-06 | 2005-09-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue ß-Ketoamid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| US7605176B2 (en) | 2004-03-06 | 2009-10-20 | Boehringer Ingelheim International Gmbh | β-ketoamide compounds with MCH antagonistic activity |
| EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER |
| DE102004017934A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| US7524862B2 (en) | 2004-04-14 | 2009-04-28 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
| WO2006066174A1 (en) * | 2004-12-17 | 2006-06-22 | Eli Lilly And Company | Thiazolopyridinone derivates as mch receptor antagonists |
| US7790731B2 (en) * | 2005-02-14 | 2010-09-07 | Banyu Pharmaceutical Co. Ltd. | Crystal form of 2-methyl-3-{4-[3-(1-pyrrolidinyl)propoxy]phenyl}-5-trifluoromethyl-4(3H)-quinazolinone |
| JP5000490B2 (ja) * | 2005-04-28 | 2012-08-15 | 武田薬品工業株式会社 | チエノピリミドン化合物 |
| WO2007011286A1 (en) * | 2005-07-15 | 2007-01-25 | Astrazeneca Ab | Therapeutic agents |
| UA91560C2 (ru) * | 2005-08-31 | 2010-08-10 | Селджин Корпорэйшн | Соединения ряда изоиндолимидов, их композиция и применение |
| PL1939204T6 (pl) * | 2005-10-19 | 2024-03-25 | Kissei Pharmaceutical Co., Ltd. | Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja oraz jej zastosowanie medyczne |
| AR056155A1 (es) * | 2005-10-26 | 2007-09-19 | Bristol Myers Squibb Co | Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica |
| US7745447B2 (en) | 2005-10-26 | 2010-06-29 | Bristol-Myers Squibb Company | Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists |
| CA2626220A1 (en) | 2005-12-21 | 2007-06-28 | Janssen Pharmaceutica N.V. | Novel substituted pyrazinone derivatives for use in mch-1 mediated diseases |
| US7553836B2 (en) | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
| WO2007093364A1 (en) | 2006-02-15 | 2007-08-23 | Sanofi-Aventis | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments |
| WO2007093365A2 (en) | 2006-02-15 | 2007-08-23 | Sanofi-Aventis | Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments |
| KR20080094699A (ko) | 2006-02-15 | 2008-10-23 | 사노피-아벤티스 | 신규 아미노알콜-치환된 아릴디하이드로이소퀴놀리논, 이의제조 방법 및 이의 약물로서의 용도 |
| BRPI0707869A2 (pt) | 2006-02-15 | 2011-05-10 | Sanofi Aventis | ariltienopirimidinonas substituÍdas com azaciclil, processo para a sua preparaÇço e seus usos como medicamentos |
| WO2007142217A1 (ja) * | 2006-06-07 | 2007-12-13 | Banyu Pharmaceutical Co., Ltd. | １－フェニルピリドン誘導体 |
| MX2008015486A (es) | 2006-06-08 | 2009-01-12 | Lilly Co Eli | Nuevos receptores antagonistas de la hormona concentrador de melanina (mch). |
| EA015127B1 (ru) * | 2006-06-08 | 2011-06-30 | Эли Лилли Энд Компани | Антагонисты мсн-рецепторов |
| EP2061767B1 (de) | 2006-08-08 | 2014-12-17 | Sanofi | Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung |
| JP2010501553A (ja) * | 2006-08-18 | 2010-01-21 | アストラゼネカ アクチボラグ | Ｍｃｈｒ１アンタゴニストとしてのチエノピリミジン−４−オン誘導体およびチエノピリダジン−７−オン誘導体 |
| EP2102208B1 (en) | 2006-12-05 | 2014-04-23 | Janssen Pharmaceutica NV | Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases |
| EA015559B1 (ru) * | 2006-12-14 | 2011-08-30 | Эли Лилли Энд Компани | ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5H-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH |
| NZ578096A (en) | 2007-01-10 | 2011-11-25 | Albany Molecular Res Inc | 5-pyridinone substituted indazoles |
| US7851622B2 (en) | 2007-04-25 | 2010-12-14 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| DE102007028925A1 (de) | 2007-06-22 | 2008-12-24 | Saltigo Gmbh | Verfahren zur Herstellung von 2-Phenoxyacetalen und den daraus korrespondierenden 2-Phenoxycarbaldehyden |
| CN101861311A (zh) | 2007-07-21 | 2010-10-13 | 阿尔巴尼分子研究公司 | 5-吡啶酮取代的吲唑 |
| JP5632612B2 (ja) * | 2007-12-05 | 2014-11-26 | あすか製薬株式会社 | ラクタム化合物又はその塩及びｐｐａｒ活性化剤 |
| PE20091928A1 (es) * | 2008-05-29 | 2009-12-31 | Bristol Myers Squibb Co | Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos |
| ES2522968T3 (es) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| CA2689707A1 (en) | 2009-11-16 | 2011-05-16 | Jean-Simon Diallo | Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening |
| KR20120060207A (ko) | 2009-08-26 | 2012-06-11 | 사노피 | 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도 |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| WO2012036233A1 (ja) * | 2010-09-17 | 2012-03-22 | 塩野義製薬株式会社 | メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体 |
| SG192941A1 (en) | 2011-02-25 | 2013-09-30 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| KR101236188B1 (ko) * | 2011-03-10 | 2013-02-22 | 한국화학연구원 | 신규한 피롤로피리디논 유도체 및 그의 ｍｃｈ 수용체-1 관련 질환에 대한 치료학적 용도 |
| HUP1100241A3 (en) | 2011-05-06 | 2013-12-30 | Richter Gedeon Nyrt | Oxetane substituted pyrimidones |
| NO3175985T3 (https=) | 2011-07-01 | 2018-04-28 | ||
| UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| RU2015106909A (ru) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | Антидиабетические трициклические соединения |
| KR20150118158A (ko) | 2013-02-22 | 2015-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 비시클릭 화합물 |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| AU2014235215A1 (en) | 2013-03-15 | 2015-10-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| BR112015030326A2 (pt) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US10294243B2 (en) | 2014-06-05 | 2019-05-21 | Bayer Cropscience Aktiengesellschaft | Bicyclic compounds as pesticides |
| SG11201804901WA (en) | 2015-12-22 | 2018-07-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| MX2019001762A (es) * | 2016-08-12 | 2019-06-12 | Bayer Cropscience Ag | Metodo para la preparacion de derivados de 4-sustituido-2,3-dihidr o-1-benzofurano mediante la ciclacion de sales de 2-(2-diazonio-6-sustituido fenil)-etanol. |
| JP7086942B2 (ja) | 2016-09-12 | 2022-06-20 | インテグラル ヘルス， インコーポレイテッド | Ｇｐｒ１２０モジュレーターとして有用な単環式化合物 |
| WO2018049328A1 (en) | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Bicyclic compounds useful as gpr120 modulators |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| EP3558298B1 (en) | 2016-12-20 | 2026-03-11 | Merck Sharp & Dohme LLC | Antidiabetic spirochroman compounds |
| EA201992780A1 (ru) | 2017-06-21 | 2020-06-02 | ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи | Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания |
| WO2019063708A1 (en) | 2017-09-29 | 2019-04-04 | Bayer Aktiengesellschaft | SUBSTITUTED 3-PHENYLQUINAZOLIN-4 (3H) -ONES AND USES THEREOF |
| UY37907A (es) | 2017-09-29 | 2019-04-30 | Bayer Ag | 3-fenilquinazolin-4 (3h)-onas sustituidas y sus usos |
| US12391705B2 (en) | 2018-12-19 | 2025-08-19 | Shy Therapeutics, Llc | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| CN110563730B (zh) * | 2019-07-29 | 2022-03-25 | 江苏理工学院 | 高纯度n10-三氟乙酰蝶酸的制备方法 |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| CN113651800B (zh) * | 2021-09-07 | 2022-08-19 | 山东铂源药业股份有限公司 | 一种甲磺酸奥希替尼的制备方法 |
| WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL137227B2 (en) * | 1984-03-28 | 1986-05-31 | Univ Lodzki | Process for preparing novel n-/dialkylaminoalkoxyphenyl/-imides of tetrahydrophtalic acids |
| ES2199366T3 (es) * | 1996-12-31 | 2004-02-16 | Dr. Reddy's Laboratories Ltd. | Compuestos heterociclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen y su uso en el tratamiento de diabetes y enfermedades relacionadas. |
| EP1218336A2 (en) * | 1999-09-20 | 2002-07-03 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
-
2001
- 2001-10-15 GB GBGB0124627.1A patent/GB0124627D0/en not_active Ceased
-
2002
- 2002-10-15 HU HU0402346A patent/HUP0402346A2/hu unknown
- 2002-10-15 CN CNA028235932A patent/CN1596247A/zh active Pending
- 2002-10-15 CA CA002463509A patent/CA2463509A1/en not_active Abandoned
- 2002-10-15 KR KR1020047005548A patent/KR20050043724A/ko not_active Withdrawn
- 2002-10-15 JP JP2003536220A patent/JP2005508966A/ja active Pending
- 2002-10-15 PL PL02370587A patent/PL370587A1/xx not_active Application Discontinuation
- 2002-10-15 CZ CZ2004498A patent/CZ2004498A3/cs unknown
- 2002-10-15 KR KR10-2004-7005546A patent/KR20040045833A/ko not_active Withdrawn
- 2002-10-15 EP EP02801693A patent/EP1436267B1/en not_active Expired - Lifetime
- 2002-10-15 CZ CZ2004499A patent/CZ2004499A3/cs unknown
- 2002-10-15 JP JP2003536216A patent/JP2005510487A/ja active Pending
- 2002-10-15 AT AT02801693T patent/ATE349434T1/de not_active IP Right Cessation
- 2002-10-15 RU RU2004110053/04A patent/RU2004110053A/ru not_active Application Discontinuation
- 2002-10-15 BR BR0213242-7A patent/BR0213242A/pt not_active Application Discontinuation
- 2002-10-15 DE DE60218721T patent/DE60218721T2/de not_active Expired - Fee Related
- 2002-10-15 MX MXPA04003534A patent/MXPA04003534A/es unknown
- 2002-10-15 PL PL02370138A patent/PL370138A1/xx not_active Application Discontinuation
- 2002-10-15 IL IL16087202A patent/IL160872A0/xx unknown
- 2002-10-15 AT AT02801692T patent/ATE356119T1/de not_active IP Right Cessation
- 2002-10-15 CN CNA028204522A patent/CN1571774A/zh active Pending
- 2002-10-15 WO PCT/US2002/032739 patent/WO2003033476A1/en not_active Ceased
- 2002-10-15 EP EP02801692A patent/EP1442025B1/en not_active Expired - Lifetime
- 2002-10-15 WO PCT/US2002/032740 patent/WO2003033480A1/en not_active Ceased
- 2002-10-15 CA CA002463508A patent/CA2463508A1/en not_active Abandoned
- 2002-10-15 MX MXPA04003532A patent/MXPA04003532A/es unknown
- 2002-10-15 DE DE60217147T patent/DE60217147T2/de not_active Expired - Fee Related
- 2002-10-15 HU HU0402335A patent/HUP0402335A3/hu unknown
- 2002-10-15 IL IL16107402A patent/IL161074A0/xx unknown
- 2002-10-15 ES ES02801693T patent/ES2279009T3/es not_active Expired - Lifetime
- 2002-10-15 ES ES02801692T patent/ES2283647T3/es not_active Expired - Lifetime
- 2002-10-15 NZ NZ531911A patent/NZ531911A/en unknown
- 2002-10-15 BR BR0213040-8A patent/BR0213040A/pt not_active IP Right Cessation
-
2004
- 2004-04-05 ZA ZA200402672A patent/ZA200402672B/en unknown
- 2004-04-13 ZA ZA200402814A patent/ZA200402814B/en unknown
- 2004-04-13 NO NO20041503A patent/NO20041503L/no not_active Application Discontinuation
- 2004-04-13 NO NO20041504A patent/NO20041504L/no not_active Application Discontinuation
- 2004-04-14 CO CO04034241A patent/CO5580779A2/es not_active Application Discontinuation
- 2004-04-14 CO CO04034243A patent/CO5580778A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004110053A (ru) | Производные лактама в качестве антагонистов 11cby рецепторов человека | |
| JP2005508966A5 (https=) | ||
| CA2432578C (en) | Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists | |
| AU2014350729B2 (en) | N-benzyl tryptanthrin derivative, and preparation method and application thereof | |
| AU2002255284B2 (en) | Quinoline derivative having azolyl group and quinazoline derivative | |
| KR0142189B1 (ko) | 치환된 피리미딘 유도체 | |
| US7232824B2 (en) | Quinazoline derivatives as medicaments | |
| JP2006522812A5 (https=) | ||
| JP2022517723A (ja) | Ｃｄｋ阻害剤としての大環状化合物、その製造方法及びその医薬品における応用 | |
| KR20110099790A (ko) | 치환된 5,6-디히드로-6-페닐벤조［ｆ］이소퀴놀린-2-아민 화합물 | |
| JP2003522761A (ja) | Ｃｏｘ−２の選択的阻害剤としてのピリミジン誘導体 | |
| CA2037630A1 (en) | Nitrogen-containing heterocylic compounds, their production and use | |
| ZA200500135B (en) | Ether substituted imidazopyridines | |
| CA2508681A1 (en) | Quinoline compounds for use in mch receptor related disorders | |
| RU2198888C2 (ru) | 3-замещенные производные 3,4,5,6,7,8-гексагидропиридо[4',3':4,5]-тиено[2,3-d]пиримидина | |
| Brandt et al. | Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl) nicotinonitrile scaffold | |
| JP2018520190A (ja) | アニリンピリミジン誘導体及びその使用 | |
| FI94953C (fi) | Menetelmä terapeuttisesti käyttökelpoisten 2-aminopyrimidiini-4-karboksamidijohdannaisten valmistamiseksi | |
| WO2016200840A1 (en) | Mono and bicyclic ring boronic acid, ester and salt compounds as inhibitors of p97 complex | |
| EP0305093B1 (en) | Imidazo(1,2-b)pyridazine derivatives | |
| JPH06501023A (ja) | 抗腫瘍活性を増強するためのピリミジン誘導体 | |
| US5158953A (en) | 2-substituted methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-ones (thiones), the preparation and use thereof | |
| Attia et al. | Synthesis and pharmacological evaluation of pentacyclic 6a, 7-dihydrodiindole and 2, 3-dihydrodiindole derivatives as novel melatoninergic ligands | |
| CZ2001235A3 (cs) | Arylpiperazinové deriváty vhodné jako uroselektivní alfa 1-adrenoceptorové blokátory | |
| JP6255509B2 (ja) | 縮合アクリジン誘導体及びその医薬組成物、製造方法及び応用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20050921 |